---
title: "Radiotherapy After Breast-Conserving Surgery in T1-2N0M0 Luminal (HR+/HER2-) Breast Cancer by Tumo"
id: "pubmed-42844798"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42844798"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42844798/"
doi: "10.12659/MSM.953757"
published_at: "2026-10-08T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Radiotherapy After Breast-Conserving Surgery in T1-2N0M0 Luminal (HR+/HER2-) Breast Cancer by Tumo
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42844798
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42844798/)
- **DOI:** [10.12659/MSM.953757](https://doi.org/10.12659%2FMSM.953757)
- **Published At:** 2026-10-08T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This observational study used the SEER database (2010–2017) to evaluate the association of adjuvant **radiotherapy** (RT) with breast cancer–specific survival (BCSS) after **breast-conserving surgery** in T1-2N0M0 luminal (HR+/HER2-) breast cancer. - A total of **5,831** patients who underwent breast-conserving surgery were identified and stratified by receipt of postoperative RT. - Survival analyses included Kaplan–Meier estimates, multivariable Cox proportional-hazards regression, and Fine–Gray competing-risk models to account for non–breast cancer deaths. - In multivariable Cox analysis, RT was independently associated with a lower hazard of breast cancer–specific death (hazard ratio [HR] = **0.623**, 95% CI: **0.512–0.792**, P < 0.001). - In the competing-risk Fine–Gray model the subdistribution hazard ratio for RT was **0.661** (95% CI: **0.530–0.825**, P < 0.001), supporting the primary result after accounting for competing events. - A statistically significant interaction between RT and primary **tumor quadrant** location was observed (interaction P = **0.019**), indicating the RT–BCSS association varied by quadrant. - Quadrant-stratified analyses showed a significant adjusted benefit of RT for tumors located in the **upper-inner** and **lower-outer** quadrants; estimates for **upper-outer** and **lower-inner** quadrants trended similarly but were not statistically significant. - Sensitivity analyses using the Fine–Gray model and E-value calculations were reported as consistent with primary findings. - Authors conclude the findings generate the hypothesis that the association between postoperative RT and BCSS varies by tumor quadrant, and they emphasize the need for prospective validation before using these results to individualize treatment decisions.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42844798/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42844798%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42844798/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42844798/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42844798/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42844798/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42844798/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42844798%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42844798%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42844798/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42844798/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42844798/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42844798/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42844798/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42844798/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42844798/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42844798/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42844798/#substances) Title & authors Abstract MeSH terms Substances Med Sci Monit Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Med+Sci+Monit%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Med+Sci+Monit%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) . 2026 Oct 8:32:e953757. doi: 10.12659/MSM.953757. # Role of Radiotherapy After Breast-Conserving Surgery in T1-2N0M0 Luminal (HR+/HER2-) Breast Cancer Stratified by Tumor Quadrant Location [Yajing Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+Y&cauthor_id=42844798)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42844798/#full-view-affiliation-1 "Department of Breast and Thyroid Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China."), [Hao Wu](https://pubmed.ncbi.nlm.nih.gov/?term=Wu+H&cauthor_id=42844798)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42844798/#full-view-affiliation-2 "Department of Breast and Thyroid Surgery, Wuxi Huishan District People's Hospital, Wuxi, Jiangsu, China.") Affiliations Expand ### Affiliations * 1 Department of Breast and Thyroid Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China. * 2 Department of Breast and Thyroid Surgery, Wuxi Huishan District People's Hospital, Wuxi, Jiangsu, China. * PMID: **42844798** * DOI: [ 10.12659/MSM.953757 ](https://doi.org/10.12659/msm.953757) Item in Clipboard # Role of Radiotherapy After Breast-Conserving Surgery in T1-2N0M0 Luminal (HR+/HER2-) Breast Cancer Stratified by Tumor Quadrant Location Yajing Huang et al. Med Sci Monit. 2026. Show details Display options Display options Format Abstract PubMed PMID Med Sci Monit Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Med+Sci+Monit%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Med+Sci+Monit%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) . 2026 Oct 8:32:e953757. doi: 10.12659/MSM.953757. ### Authors [Yajing Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+Y&cauthor_id=42844798)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42844798/#short-view-affiliation-1 "Department of Breast and Thyroid Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China."), [Hao Wu](https://pubmed.ncbi.nlm.nih.gov/?term=Wu+H&cauthor_id=42844798)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42844798/#short-view-affiliation-2 "Department of Breast and Thyroid Surgery, Wuxi Huishan District People's Hospital, Wuxi, Jiangsu, China.") ### Affiliations * 1 Department of Breast and Thyroid Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China. * 2 Department of Breast and Thyroid Surgery, Wuxi Huishan District People's Hospital, Wuxi, Jiangsu, China. * PMID: **42844798** * DOI: [ 10.12659/MSM.953757 ](https://doi.org/10.12659/msm.953757) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract BACKGROUND The survival association of adjuvant radiotherapy (RT) in early-stage node-negative luminal (HR+/HER2-) breast cancer remains under evaluation, and whether this association is modified by tumor quadrant location is unknown. MATERIAL AND METHODS We identified 5831 patients with T1-2N0M0 luminal breast cancer treated with breast-conserving surgery from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2017), stratified by RT receipt. Breast cancer-specific survival (BCSS) was analyzed using Kaplan-Meier, Cox regression, and Fine-Gray competing-risk models, with a prespecified RT-by-quadrant interaction test. RESULTS RT was independently associated with a lower hazard of breast cancer-specific death (hazard ratio=0.623, 95% confidence interval: 0.512-0.792, P<0.001) in the Cox regression analysis. In the competing-risk Fine-Gray model, the subdistribution hazard ratio was 0.661 (95% confidence interval: 0.530-0.825, P<0.001). A significant interaction was observed between RT and tumor quadrant (P=0.019). Quadrant-stratified analyses showed a significant adjusted association between RT and a lower hazard of breast cancer-specific death for upper-inner and lower-outer quadrant tumors; estimates for upper-outer and lower-inner quadrant tumors were in the same direction but did not display statistical significance. Sensitivity analyses using the Fine-Gray model and E-value calculations were consistent with the primary findings. CONCLUSIONS In this observational study of T1-2N0M0 luminal breast cancer, a significant statistical interaction was observed between postoperative RT and tumor quadrant location, generating the hypothesis that the association between RT and BCSS varies according to primary tumor quadrant. These findings require prospective validation before informing individualized treatment decisions. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Breast Neoplasms* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Breast Neoplasms* / mortality Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fmortality%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Breast Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Breast Neoplasms* / radiotherapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fradiotherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Breast Neoplasms* / surgery Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fsurgery%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Erb-b2 Receptor Tyrosine Kinases / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Erb-b2+Receptor+Tyrosine+Kinases%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Erb-b2+Receptor+Tyrosine+Kinases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Kaplan-Meier Estimate Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Kaplan-Meier+Estimate%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Kaplan-Meier+Estimate) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Mastectomy, Segmental* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mastectomy%2C+Segmental%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mastectomy%2C+Segmental) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Middle Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Neoplasm Staging Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasm+Staging%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasm+Staging) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Proportional Hazards Models Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Proportional+Hazards+Models%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Proportional+Hazards+Models) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * Radiotherapy, Adjuvant / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Radiotherapy%2C+Adjuvant%2Fmethods%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Radiotherapy%2C+Adjuvant) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) * SEER Program Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22SEER+Program%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=SEER+Program) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) ## Substances * Erb-b2 Receptor Tyrosine Kinases Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Erb-b2+Receptor+Tyrosine+Kinases%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Erb-b2+Receptor+Tyrosine+Kinases%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42844798/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42844798/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42844798%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42844798/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42844798%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42844798%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42844798/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/)
## Related Clinical Research

- [CBC-derived inflammatory indices in colorectal cancer: diagnostic and prognostic head-to-head anal](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-complete-blood-count-derived-inflammation-indices-in-colorectal-cancer-head-to.md)
- [SHROOM3 regulates leading-edge protrusion stability and Wnt/PCP-driven migration in breast cancer](https://medichelpline.com/clinical-feed/biorxiv-5-shroom3-promotes-leading-edge-protrusion-stability-and-wnt-planar-cell-polarity.md)
- [AI prognostic CTX score predicts DFS and suggests chemo benefit in node-positive HR+ breast cancer](https://medichelpline.com/clinical-feed/medrxiv-7-ai-based-prognosis-and-chemotherapy-benefit-in-node-positive-hr-breast-cancer-a.md)
- [ANO6 scaffolds ER–mitochondria contacts to sequester lipids and enable ferroptosis evasion in chem](https://medichelpline.com/clinical-feed/biorxiv-4-ano6-scaffolds-er-mitochondria-contacts-to-govern-spatial-lipid.md)
- [LLM Framework Extracts Biomarkers and Identifies Triple-Negative Breast Cancer from Pathology Repo](https://medichelpline.com/clinical-feed/pubmed-42913472.md) (DOI: 10.2196/97117)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.